Imetelstat: a new addition to the therapeutic landscape of lower-risk MDS
Imetelstat is an oligonucleotide telomerase inhibitor recently approved by the US Food and Drug Administration for adults with lower-risk myelodysplasia wh
Related Articles
Emerging HER2-Directed Agents May Address Resistance to SOC Regimens in Pretreated HER2+ Breast Cancer
Ian Krop, MD, PhD, spotlights emerging HER2-directed agents of interest for pretreated patients with HER2-positive breast cancer.
Evolutionary cell biologist Dr. Grant King named a Hanna Gray Fellow
The Howard Hughes Medical Institute has named Fred Hutch Cancer Center postdoctoral researcher Grant King, PhD, a Hanna H. Gray Fellow — investing up to…
Cellular Therapies and Novel Targeted Agents Will Shape the Future of R/R ALL Management
Marlise Luskin, MD, MSCE, discusses the treatment paradigm for relapsed/refractory ALL and research seeking to integrate agents into the frontline setting
How blood and bone marrow transplant expertise is changing cancer care at Ohio State
For four decades, Ohio State blood and bone marrow transplant innovation has improved cancer care with an increasing emphasis on patients’ quality of life.
FDA Fast Tracks Abenacianine for Lung Cancer Surgery
Abenacianine, a tumor-targeted fluorescent imaging agent, received fast track designation from the FDA after demonstrating its safety and efficacy in visualizing lung tumors in a…
Research Funding
AACR grants fund cancers researchers worldwide at every career stage, representing a commitment to the understanding of cancer biology, prevention, early detection, interception, and cure.
Phase 3 RCC Data Reinforce Efficacy of Standard IO/TKI Doublets Across IMDC Risk Groups
Yousef Zakharia, MD, spotlights findings from 3 key trials informing the use of standard IO/TKI regimens in metastatic clear cell renal cell carcinoma.
Trump’s cataclysmic damage is going way beyond tariffs
The functioning of US government is facing a systemic crisis
Comparing the UK & US Approaches to First-Line Treatment in Hodgkin Lymphoma
Comparing the UK & US Approaches to First-Line Treatment in Hodgkin Lymphoma
Many Cancer Patients May Be Unwilling to Participate in Clinical Trials, Survey Suggests
Being well-informed about clinical trials was associated with a greater willingness to participate.
